Generic name prescription rule in India: the NMC text Capital letters, brand names, the 2025 court order, and a compliant Rx line by line.

Short answer: the generic name prescription rule for doctors in India is clause 1.5 of the 2002 conduct regulations, which the NMC applies today. Since 8 October 2016 it reads: "Every physician should prescribe drugs with generic names legibly and preferably in capital letters and he/she shall ensure that there is a rational prescription and use of drugs". It asks for the generic name, for writing a chemist and a patient can read, and prefers capital letters; it does not say anything about brand names in brackets. A Punjab and Haryana High Court order of 27 August 2025 and an NMC notice of December 2025 repeated the rule, but neither changed its words for a private clinic.

Our NMC professional conduct guide covers the whole 2002 code clause by clause. This post stays on one narrow question: what clause 1.5 and the documents around it ask of the prescription itself, and what a compliant one looks like at a small OPD.

What does the generic name rule actually say?

The Indian Medical Council (Professional Conduct, Etiquette and Ethics) Regulations, 2002 were published in the Gazette of India on 6 April 2002. In its original form, clause 1.5, headed "Use of Generic names of drugs", said: "Every physician should, as far as possible, prescribe drugs with generic names and he / she shall ensure that there is a rational prescription and use of drugs."

The NMC's copy of the regulations records that clause 1.5 "is substituted in terms of Notification published in the Gazette of India on 08.10.2016". The new text is:

Every physician should prescribe drugs with generic names legibly and preferably in capital letters and he/she shall ensure that there is a rational prescription and use of drugs

Three changes sit in those words. The phrase "as far as possible" is gone from the generic-name part. Two new requirements arrive: "legibly", and "preferably in capital letters". The rational-use duty stays as it was. The NMC's December 2025 notice refers to this amendment as "the MCI Notification dated 21.09.2016", which is the date the Medical Council of India issued it; 8 October 2016 is when it appeared in the Gazette.

Read the verbs as written. The clause says a physician "should" prescribe with generic names, legibly, "preferably" in capitals, and "shall" ensure rational prescription. It does not define "generic name". The 2023 regulations that never took effect did offer a definition, which we come to below: the "Non-Proprietary or approved name of a drug". Your state medical council decides how strictly to read "should" and "preferably" in a complaint, and clause 7.1 lists "any violation of these Regulations" as professional misconduct.

Is the 2002 rule still in force after the 2023 NMC regulations?

Yes. On 2 August 2023 the NMC notified the National Medical Commission Registered Medical Practitioner (Professional Conduct) Regulations, 2023. On 23 August 2023, by notification No. R-12013/01/2022/Ethics (Gazette of India No. 596, 24 August 2023), it held them "in abeyance with immediate effect", said they "shall not be operative and effective till further Gazette Notification on the subject", and adopted the 2002 regulations "as if the same have been made by the Commission" under the NMC Act, 2019. We checked the first seven pages of the NMC's What's New listing on 26 October 2026 and found no notification bringing the 2023 text back, and nothing newer on generic prescribing than the December 2025 notice below.

The 2023 text is worth knowing only because forwards quote it as if it were law. Regulation 8 said: "Every RMP should prescribe drugs using generic names written legibly and prescribe drugs rationally, avoiding unnecessary medications and irrational fixed-dose combination tablets." Attached "Generic Medicine and Prescription Guidelines" went further. Here is how the two compare:

If the NMC re-notifies these regulations, or a revised version, the right-hand column is what to re-check. Until then it is guidance you may agree with, not a rule your council can hold you to.

What did the 2025 High Court order and the NMC notice change?

The order came out of a bail matter. According to the NMC's own notice, the Punjab and Haryana High Court passed an order dated 27 August 2025 in Yogesh vs. State of Haryana (CRM-M-30305-2024). We could not retrieve the order from the court's website, so what follows is how the NMC describes it. The notice says the court "observed that a legible medical prescription/document is an essential component of the Right to Health under Article 21 of the Constitution of India", and that it referred to the NMC Act, 2019, the 2002 regulations and the 21 September 2016 MCI notification, "all of which mandate that every medical practitioner must write prescriptions legibly and preferably in capital letters." It adds that the court referred to the Clinical Establishments Act, 2010 and its rules on electronic health records.

The NMC's response was Public Notice No. N-P016 (11)2/2023-PGMEB-NMC dated 11 December 2025 from its Post-Graduate Medical Education Board, sent on by letter No. NMC/LEGAL/25436 dated 15 December 2025. It does three things:

• It asks the NMC to ensure "the inclusion and reinforcement of the importance of legible and clear handwriting in medical prescriptions in the curriculum of all medical colleges/institutions in India".
• It tells "every medical college" to set up a sub-committee under its Drugs and Therapeutics Committee to appraise prescriptions, "identify deviations", record findings in the committee's minutes and make them available to the NMC.
• It reminds "all medical institutions" of clause 1.5, quoting it, and says "Compliance of these directions is mandatory."

The covering letter is addressed to "The Principal/Dean, All the Medical Colleges/Medical Institutions of India", and the notice to state health secretaries, directors of medical education and medical institutions. A private OPD with no teaching attached will not get a DTC sub-committee audit under this notice. What the notice does show is that the NMC reads clause 1.5 as a live, enforceable rule, and that a court has tied legibility to a patient's rights. A complaint about an unreadable prescription from a private clinic would still go to the state medical council under clause 8.2, judged against clause 1.5 itself.

What does "legibly, preferably in capital letters" mean in practice?

The clause does not say whether it covers handwritten or printed prescriptions; it covers both because it covers every prescription. It sets two tests. "Legibly" is the requirement. "Preferably in capital letters" is the stated preference for how to meet it.

For a handwritten parchi, that means block capitals for the drug name, at least, and handwriting a chemist at another counter can read without calling you. The NMC notice's focus is "legible and clear handwriting", so this is where complaints start.

For a typed or printed prescription, legibility is mostly solved by the printer. The capital-letter preference still has a reference format. Annexure 2 of the Telemedicine Practice Guidelines of 25 March 2020, which state that they constitute "Appendix 5" of the 2002 regulations, gives a sample prescription where each medicine line reads: "NAME OF MEDICINE (in capital letters only with generic name) drug form, strength, frequency of administration & duration." That sample is written for teleconsultation, but it is the only official layout we found that spells out how the capital-letter preference looks on a typed prescription. The 2023 guidelines, not in force, said "As far as possible prescriptions should be typed and printed to avoid errors".

A practical reading for a clinic: print the generic name in capitals, keep the strength, form, frequency and duration on the same line in plain case if you prefer, and avoid shorthand the patient cannot read back. Do not let a template shrink the font to fit a long list on A5; legibility is the test. This is about how the prescription reads, not what to prescribe; drug choice, doses and substitutions are your clinical decision.

Can I write the brand name in brackets after the generic name?

The rule in force does not answer this directly, so here is only what the texts say.

• Clause 1.5 (in force) asks for generic names. It does not mention brand names, brackets, or a ban on adding a brand.
• Clause 6.3 (in force), in the section on dispensing, says: "Drugs prescribed by a physician or brought from the market for a patient should explicitly state the proprietary formulae as well as generic name of the drug." That sentence speaks of both the proprietary formula and the generic name.
• Clause 3.7.1 (in force) says the "Prescription should also make clear if the Physician himself dispensed any medicine."
• The 2023 guidelines (not in force) said generic names "only", with a relaxation for narrow therapeutic index drugs and biosimilars, and "Avoid prescribing 'branded' generic drugs." Their regulation 12 B would have required that drugs prescribed or bought from the pharmacy "explicitly state the generic name of the drug", dropping the proprietary formula.

So under the text in force, a prescription that leads with the generic name in capitals is what clause 1.5 asks for. Whether adding a brand in brackets is acceptable, discouraged or a problem is a question of interpretation that your state medical council answers, not this post. If you need a firm answer, write to your council's registrar and keep the reply; contact details are on our state medical councils list.

What does a compliant prescription look like, line by line?

Several clauses of the 2002 regulations decide what sits on the prescription paper besides clause 1.5. Here is each line with the clause that asks for it.

Two notes on the table. The Annexure 2 layout is the sample for teleconsultation; for an in-person visit the 2002 regulations do not prescribe a full layout, so treat the sample as a reference, not a form you must copy. And clause 7.13 cuts both ways: the prescription paper carries the same content as the signboard, so a photograph, a slogan or a list of "specialities" you do not hold does not belong on it. Clause 6.1.2 separately calls "Printing of self photograph" on a letterhead self-advertisement.

If you want to see these lines laid out on an A4 or A5 page, our free prescription format tool builds a letterhead in the browser with the registration number in the right place. Records of what you prescribed follow the rules in our post on how long to keep medical records.

A quick check before you print a new pad

1. Your full name and designation are on the letterhead (3.7.2).
2. Only recognised qualifications follow your name (1.4.2, 7.13).
3. Your registration number and the name of the council that issued it are printed, not handwritten each time (1.4.1, 7.13).
4. No photograph or publicity material on the pad (6.1.2).
5. The medicine area leaves room to write each generic name in capitals on its own line (1.5).
6. There is a way to mark medicines you dispensed yourself (3.7.1).
7. If you consult on the phone or video too, a line saying the prescription was generated on a teleconsultation, as in Annexure 2.
8. Every prescription is copied or saved, so you can produce it when a record request arrives.